Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 1
2004 1
2007 2
2008 1
2009 1
2010 2
2011 3
2012 3
2013 1
2014 2
2015 1
2016 2
2017 1
2018 4
2019 3
2020 6
2021 6
2022 3
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Khunger M, et al. Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10. Chest. 2017. PMID: 28499515 Review.
BACKGROUND: Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune-mediated pneumonitis …
BACKGROUND: Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small …
A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.
Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao N, Fu B, Zhu Z, Shi Y, Liu J, Wu R, Wang C, Yao S, Li Y. Chen L, et al. Sci Rep. 2018 Jan 23;8(1):1439. doi: 10.1038/s41598-018-19949-z. Sci Rep. 2018. PMID: 29362385 Free PMC article. Review.
The relationship between O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and clinicopathological characteristics of non-small-cell lung carcinoma (NSCLC) has remained controversial and unclear. ...
The relationship between O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and clinicopathological characteristics of n …
MALAT-1 Expression Correlates with Prognosis in Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Ran R, Jin JW, Zhang WP. Ran R, et al. Dis Markers. 2021 Nov 23;2021:5424623. doi: 10.1155/2021/5424623. eCollection 2021. Dis Markers. 2021. PMID: 34858541 Free PMC article.
BACKGROUND: Non-small-cell lung carcinoma (abbreviated as NSCLC) progresses rapidly and lacks appropriate biological markers. ...
BACKGROUND: Non-small-cell lung carcinoma (abbreviated as NSCLC) progresses rapidly and lacks appropriate …
Clinicopathological significance and a potential drugtarget of RARbeta in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X, Shi K, Zhou SJ, Yu DP, Liu Z, Han Y. Song X, et al. Drug Des Devel Ther. 2016 Apr 6;10:1345-54. doi: 10.2147/DDDT.S96766. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27103788 Free PMC article. Review.
Aberrant RARbeta promoter methylation has been frequently investigated in non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. ...
Aberrant RARbeta promoter methylation has been frequently investigated in non-small-cell lung carcinoma ( …
Oncologic Outcomes of Surgery Versus SBRT for Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Ijsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg AKC, Tsai TC, Ten Broek RPG, Lebenthal A. Ijsseldijk MA, et al. Clin Lung Cancer. 2021 May;22(3):e235-e292. doi: 10.1016/j.cllc.2020.04.017. Epub 2020 May 7. Clin Lung Cancer. 2021. PMID: 32912754
BACKGROUND: The optimal treatment of stage I non-small-cell lung carcinoma is subject to debate. The aim of this study was to compare overall survival and oncologic outcomes of lobar resection (LR), sublobar resection (SR), and stereotactic body …
BACKGROUND: The optimal treatment of stage I non-small-cell lung carcinoma is subject to debate. The aim …
Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: a meta-analysis.
Yang Y, Luo J, Zhai X, Fu Z, Tang Z, Liu L, Chen M, Zhu Y. Yang Y, et al. Int J Cancer. 2014 Sep 15;135(6):1417-24. doi: 10.1002/ijc.28788. Epub 2014 Mar 4. Int J Cancer. 2014. PMID: 24523200 Free article. Review.
In this study, we conducted a systematic review and meta-analysis to assess the prognostic value of p-Akt in patients with non-small cell lung carcinoma (NSCLC). Relevant articles were identified by searching MEDLINE. ...
In this study, we conducted a systematic review and meta-analysis to assess the prognostic value of p-Akt in patients with non-sma …
Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma.
Boudy AS, Grausz N, Selleret L, Gligorov J, Thomassin-Naggara I, Touboul C, Daraï E, Cadranel J. Boudy AS, et al. Lung Cancer. 2021 Nov;161:68-75. doi: 10.1016/j.lungcan.2021.09.001. Epub 2021 Sep 11. Lung Cancer. 2021. PMID: 34543940
The use of tyrosine kinase inhibitor (TKI) therapy for advanced oncogenic-driven non-small cell lung carcinoma (NSCLC) has improved overall survival. ...
The use of tyrosine kinase inhibitor (TKI) therapy for advanced oncogenic-driven non-small cell lung carcinom …
45 results